Renaissance Technologies LLC Has $954,000 Stock Holdings in Agenus Inc. $AGEN

Renaissance Technologies LLC decreased its position in shares of Agenus Inc. (NASDAQ:AGEN) by 47.4% during the 1st quarter, Holdings Channel reports. The institutional investor owned 285,646 shares of the biotechnology company’s stock after selling 257,900 shares during the quarter. Renaissance Technologies LLC’s holdings in Agenus were worth $954,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. Invesco Ltd. bought a new stake in shares of Agenus in the first quarter valued at about $88,000. Price T Rowe Associates Inc. MD acquired a new stake in Agenus in the 4th quarter worth about $77,000. LPL Financial LLC boosted its holdings in Agenus by 20.3% in the 4th quarter. LPL Financial LLC now owns 23,326 shares of the biotechnology company’s stock valued at $73,000 after purchasing an additional 3,943 shares during the period. Sherbrooke Park Advisers LLC bought a new stake in Agenus in the 3rd quarter valued at about $64,000. Finally, Acadian Asset Management LLC acquired a new position in shares of Agenus during the 1st quarter worth approximately $58,000. Institutional investors and hedge funds own 61.46% of the company’s stock.

Agenus Stock Up 4.6%

AGEN opened at $7.32 on Friday. The stock has a market capitalization of $329.55 million, a price-to-earnings ratio of 2.84 and a beta of 1.41. Agenus Inc. has a twelve month low of $2.71 and a twelve month high of $8.85. The company has a 50-day simple moving average of $4.84 and a 200 day simple moving average of $3.94.

Agenus (NASDAQ:AGEN) last released its earnings results on Friday, August 7th. The biotechnology company reported ($0.01) EPS for the quarter, missing the consensus estimate of $0.05 by ($0.06). Agenus had a net margin of 69.33% and a negative return on equity of 47.68%. The firm had revenue of $34.52 million during the quarter, compared to the consensus estimate of $34.00 million. Sell-side analysts anticipate that Agenus Inc. will post -0.28 EPS for the current fiscal year.

Wall Street Analyst Weigh In

AGEN has been the topic of several recent research reports. Zacks Research cut shares of Agenus from a “strong-buy” rating to a “hold” rating in a report on Monday, May 11th. Wall Street Zen upgraded Agenus from a “buy” rating to a “strong-buy” rating in a research note on Sunday, August 9th. Weiss Ratings raised Agenus from a “sell (d)” rating to a “sell (d+)” rating in a research report on Friday, August 7th. HC Wainwright restated a “buy” rating and set a $25.00 price objective (down from $30.00) on shares of Agenus in a research note on Tuesday. Finally, B. Riley Financial reaffirmed a “buy” rating and issued a $14.00 price objective (up from $8.00) on shares of Agenus in a report on Thursday, July 30th. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Agenus presently has a consensus rating of “Hold” and an average target price of $19.50.

About Agenus

Agenus, Inc (NASDAQ:AGEN) is a clinical-stage immuno-oncology company headquartered in Lexington, Massachusetts. The company focuses on the discovery and development of therapies designed to modulate the immune system’s response to cancer. Leveraging proprietary platforms in checkpoint modulation, vaccine technology and adjuvant systems, Agenus aims to deliver combination regimens that enhance antitumor activity across a variety of solid tumors and hematological malignancies.

Agenus’ pipeline includes monoclonal antibodies targeting immune checkpoints, cytokine-based therapeutics and vaccine candidates built on its engineered heat shock protein (HSP) platform.